Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotarug plus Osimertinib in EGFR Exon 20 Insertion NSCLC
NCT05132777Phase 2Unknown
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of becotatug in non-small cell lung cancer (NSCLC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
becotatug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05132777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132777.